Skip to main navigation Skip to search Skip to main content

Phase I trial of {alpha}-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML.

  • Joseph G. Jurcic
  • , Farhad Ravandi
  • , John M. Pagel
  • , Jae Hong Park
  • , B. Douglas Smith
  • , Dan Douer
  • , Moshe Yair Levy
  • , Elihu Estey
  • , Hagop M. Kantarjian
  • , Dennis Earle
  • , Dragan Cicic
  • , David A. Scheinberg

Research output: Contribution to journal › Article › peer-review

Original languageAmerican English
JournalJournal of Clinical Oncology
Volume33
StatePublished - May 20 2015

Disciplines

  • Physical Therapy
  • Medicine and Health Sciences
  • Oncology

Cite this